Lazard Asset Management
RETA

Lazard Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Lazard Asset Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,338
Closed -$1.14M – 2502
2021
Q3 		$1.14M Buy
+11,338
New +$1.33M ﹤0.01% 1044

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Lazard Asset Management's RETA Position: Q4 2021 in Review

Lazard Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 11,338 shares — an estimated $1.14M sold.

Lazard Asset Management first reported a position in RETA in Q3 2021 and held it in 1 quarter. The position peaked at $1.14M in Q3 2021. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

  • Lazard Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
  • Lazard Asset Management sold 11,338 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $1.14M.
  • Lazard Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2021 and held it in 1 quarter.
  • Lazard Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.14M in Q3 2021.
  • 151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Lazard Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.